GSK
@gsk.bsky.social
We are uniting science, technology and talent to get ahead of disease together.
For Covid-19 and influenza, the risks are well-known but many people underestimate respiratory syncytial virus, or RSV.
🔗 Find out who is most at risk and how they can protect themselves: gsk.to/4icL4eL
🔗 Find out who is most at risk and how they can protect themselves: gsk.to/4icL4eL
November 22, 2025 at 10:00 AM
For Covid-19 and influenza, the risks are well-known but many people underestimate respiratory syncytial virus, or RSV.
🔗 Find out who is most at risk and how they can protect themselves: gsk.to/4icL4eL
🔗 Find out who is most at risk and how they can protect themselves: gsk.to/4icL4eL
80 years after the Nobel Prize for penicillin, antimicrobial resistance is one of societies toughest challenges. GSK, the Fleming Initiative, and the @ineosoxford.bsky.social hosted leaders at the Royal Society of Medicine to advance the global response.
November 20, 2025 at 3:28 PM
80 years after the Nobel Prize for penicillin, antimicrobial resistance is one of societies toughest challenges. GSK, the Fleming Initiative, and the @ineosoxford.bsky.social hosted leaders at the Royal Society of Medicine to advance the global response.
Every day infections are becoming harder to treat. The solutions exist. The challenge is acting fast enough, together, to make them count. Hear from experts from across science and healthcare on how we can get ahead of AMR if we act together, now.
November 19, 2025 at 3:00 PM
Every day infections are becoming harder to treat. The solutions exist. The challenge is acting fast enough, together, to make them count. Hear from experts from across science and healthcare on how we can get ahead of AMR if we act together, now.
COPD affects over 390 million people globally, significantly impacting patients like Val and their families.
This #WorldCOPDDay2025 highlights the urgent need for earlier intervention to improve lives.
This #WorldCOPDDay2025 highlights the urgent need for earlier intervention to improve lives.
November 19, 2025 at 10:00 AM
COPD affects over 390 million people globally, significantly impacting patients like Val and their families.
This #WorldCOPDDay2025 highlights the urgent need for earlier intervention to improve lives.
This #WorldCOPDDay2025 highlights the urgent need for earlier intervention to improve lives.
We’re announcing a major research programme with the Fleming Initiative to find new ways to get ahead of #AMR. We’re combining scientific expertise with cutting-edge AI technology, including funding for around 50 dedicated UK scientific and academic positions: gsk.to/4r4CrqD
November 18, 2025 at 10:59 AM
We’re announcing a major research programme with the Fleming Initiative to find new ways to get ahead of #AMR. We’re combining scientific expertise with cutting-edge AI technology, including funding for around 50 dedicated UK scientific and academic positions: gsk.to/4r4CrqD
Living with blood cancer often means lifelong treatment, frequent hospital visits, and managing challenging side effects.
But what if there are more ways to improve both care and quality of life?
🔗 Read more: bit.ly/43z2Brb
But what if there are more ways to improve both care and quality of life?
🔗 Read more: bit.ly/43z2Brb
November 13, 2025 at 10:00 AM
Living with blood cancer often means lifelong treatment, frequent hospital visits, and managing challenging side effects.
But what if there are more ways to improve both care and quality of life?
🔗 Read more: bit.ly/43z2Brb
But what if there are more ways to improve both care and quality of life?
🔗 Read more: bit.ly/43z2Brb
We’re proud to join industry leaders and key policymakers at the #SilverEconomyForum in Manchester to discuss how we can foster trust in science to get ahead of disease and build more resilient societies.
Watch this video to learn more about our approach to unlocking the power of prevention 👇
Watch this video to learn more about our approach to unlocking the power of prevention 👇
November 11, 2025 at 3:08 PM
We’re proud to join industry leaders and key policymakers at the #SilverEconomyForum in Manchester to discuss how we can foster trust in science to get ahead of disease and build more resilient societies.
Watch this video to learn more about our approach to unlocking the power of prevention 👇
Watch this video to learn more about our approach to unlocking the power of prevention 👇
#News for #investors and #media: At #TLM25 we’ll share new data from our advancing hepatology pipeline - with 21 abstracts covering CHB, MASH, ALD and PBC.
We remain committed to addressing the global burden of liver disease.
Learn more: gsk.to/3WJNqIa
We remain committed to addressing the global burden of liver disease.
Learn more: gsk.to/3WJNqIa
November 7, 2025 at 1:52 PM
#News for #investors and #media: At #TLM25 we’ll share new data from our advancing hepatology pipeline - with 21 abstracts covering CHB, MASH, ALD and PBC.
We remain committed to addressing the global burden of liver disease.
Learn more: gsk.to/3WJNqIa
We remain committed to addressing the global burden of liver disease.
Learn more: gsk.to/3WJNqIa
Join us at the American Society of Nephrology congress this week, as we partner with nephrology leaders to talk about the importance of protecting kidney function and supporting long-term health outcomes for people living with lupus.
November 5, 2025 at 3:00 PM
Join us at the American Society of Nephrology congress this week, as we partner with nephrology leaders to talk about the importance of protecting kidney function and supporting long-term health outcomes for people living with lupus.
"One person doesn’t make a difference. We all come together, and we make it happen.”
From facing cancer to co-founding the Multiple Myeloma Research Foundation, Kathy Giusti has made a huge difference to the lives of so many living with cancer.
🎥 Watch more: gsk.to/4nfiSJ7
From facing cancer to co-founding the Multiple Myeloma Research Foundation, Kathy Giusti has made a huge difference to the lives of so many living with cancer.
🎥 Watch more: gsk.to/4nfiSJ7
October 30, 2025 at 2:00 PM
"One person doesn’t make a difference. We all come together, and we make it happen.”
From facing cancer to co-founding the Multiple Myeloma Research Foundation, Kathy Giusti has made a huge difference to the lives of so many living with cancer.
🎥 Watch more: gsk.to/4nfiSJ7
From facing cancer to co-founding the Multiple Myeloma Research Foundation, Kathy Giusti has made a huge difference to the lives of so many living with cancer.
🎥 Watch more: gsk.to/4nfiSJ7
#Investors and #Media: Cautionary statement regarding forward-looking statements & the definitions & reconciliations for non-IFRS measures in our Q3 2025 results. CER% represents constant exchange rates. £% or AER% represents actual exchange rates. www.gsk.com/en-gb/invest...
Cautionary statement | GSK
Cautionary statement regarding forward-looking statements
www.gsk.com
October 29, 2025 at 7:22 AM
#Investors and #Media: Cautionary statement regarding forward-looking statements & the definitions & reconciliations for non-IFRS measures in our Q3 2025 results. CER% represents constant exchange rates. £% or AER% represents actual exchange rates. www.gsk.com/en-gb/invest...
Today we announce our Q3 2025 results, with another quarter of strong performance and upgraded guidance for 2025.
Hear more from our CEO Emma Walmsley ⤵️
More information for media and investors: gsk.com
$GSK #Q3Results
Hear more from our CEO Emma Walmsley ⤵️
More information for media and investors: gsk.com
$GSK #Q3Results
October 29, 2025 at 7:21 AM
Today we announce our Q3 2025 results, with another quarter of strong performance and upgraded guidance for 2025.
Hear more from our CEO Emma Walmsley ⤵️
More information for media and investors: gsk.com
$GSK #Q3Results
Hear more from our CEO Emma Walmsley ⤵️
More information for media and investors: gsk.com
$GSK #Q3Results
#News for #investors and #media: Today we announced an agreement with Empirico to add to our pipeline in COPD and potentially other inflammatory respiratory diseases.
Find out more: gsk.to/4oF5Vt6
Find out more: gsk.to/4oF5Vt6
October 28, 2025 at 7:15 AM
#News for #investors and #media: Today we announced an agreement with Empirico to add to our pipeline in COPD and potentially other inflammatory respiratory diseases.
Find out more: gsk.to/4oF5Vt6
Find out more: gsk.to/4oF5Vt6
#News for #Investors and #Media: Today we announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to an investigational antibody-drug conjugate in our oncology pipeline.
Learn more here: gsk.to/4hwnHfz
Learn more here: gsk.to/4hwnHfz
October 28, 2025 at 7:07 AM
#News for #Investors and #Media: Today we announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to an investigational antibody-drug conjugate in our oncology pipeline.
Learn more here: gsk.to/4hwnHfz
Learn more here: gsk.to/4hwnHfz
#News for #investors and #media: Today we announced an agreement with Syndivia to add to our growing oncology pipeline in prostate cancer.
Find out more: gsk.to/4nrTYFX
Find out more: gsk.to/4nrTYFX
October 27, 2025 at 7:04 AM
#News for #investors and #media: Today we announced an agreement with Syndivia to add to our growing oncology pipeline in prostate cancer.
Find out more: gsk.to/4nrTYFX
Find out more: gsk.to/4nrTYFX
#News for #Investors and #Media
The US Food and Drug Administration (FDA) has approved our therapy to treat an incurable and challenging blood cancer.
For more information, visit: www.gsk.com
The US Food and Drug Administration (FDA) has approved our therapy to treat an incurable and challenging blood cancer.
For more information, visit: www.gsk.com
October 23, 2025 at 8:17 PM
#News for #Investors and #Media
The US Food and Drug Administration (FDA) has approved our therapy to treat an incurable and challenging blood cancer.
For more information, visit: www.gsk.com
The US Food and Drug Administration (FDA) has approved our therapy to treat an incurable and challenging blood cancer.
For more information, visit: www.gsk.com
“Our patients - including families just like mine - are relying on us. We won't let them down.”
In this article, Hesham Abdullah shares his family's story and how his team are working tirelessly to realise a future where people don't just survive cancer but thrive long after.
🔗bit.ly/4o9ASpq
In this article, Hesham Abdullah shares his family's story and how his team are working tirelessly to realise a future where people don't just survive cancer but thrive long after.
🔗bit.ly/4o9ASpq
October 23, 2025 at 10:15 AM
“Our patients - including families just like mine - are relying on us. We won't let them down.”
In this article, Hesham Abdullah shares his family's story and how his team are working tirelessly to realise a future where people don't just survive cancer but thrive long after.
🔗bit.ly/4o9ASpq
In this article, Hesham Abdullah shares his family's story and how his team are working tirelessly to realise a future where people don't just survive cancer but thrive long after.
🔗bit.ly/4o9ASpq
We’re at #IDWeek2025 because infectious diseases remain one of the greatest public health challenges, responsible for one in six deaths worldwide. Many are still overlooked, and rising resistance is making treatment options less effective.
➡️ Want to learn more? www.gsk.com/en-gb/innova...
➡️ Want to learn more? www.gsk.com/en-gb/innova...
October 22, 2025 at 8:46 AM
We’re at #IDWeek2025 because infectious diseases remain one of the greatest public health challenges, responsible for one in six deaths worldwide. Many are still overlooked, and rising resistance is making treatment options less effective.
➡️ Want to learn more? www.gsk.com/en-gb/innova...
➡️ Want to learn more? www.gsk.com/en-gb/innova...
#News for #investors and #media: We’ve just announced data from our pivotal phase III clinical programme for a metered dose inhaler (MDI): gsk.to/4nkQipr
October 22, 2025 at 6:31 AM
#News for #investors and #media: We’ve just announced data from our pivotal phase III clinical programme for a metered dose inhaler (MDI): gsk.to/4nkQipr
Together with ViiV Healthcare, we’re investing a total of £6m in the Global Fund, to help them fund locally led programmes that are tackling the high burden of HIV, tuberculosis and malaria in lower income countries.
October 21, 2025 at 8:08 AM
Together with ViiV Healthcare, we’re investing a total of £6m in the Global Fund, to help them fund locally led programmes that are tackling the high burden of HIV, tuberculosis and malaria in lower income countries.
#News for #Investors and #Media: The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for a new prefilled syringe presentation of one of our vaccines.
Learn more: gsk.to/47egZpR
Learn more: gsk.to/47egZpR
October 21, 2025 at 7:00 AM
#News for #Investors and #Media: The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion for a new prefilled syringe presentation of one of our vaccines.
Learn more: gsk.to/47egZpR
Learn more: gsk.to/47egZpR
#News for #Media and #Investors: Today, with Spero, we are sharing an update on the Phase III trial results of one of our investigational oral anti-infectives, presented during #IDWeek2025 in Atlanta.
Learn more: gsk.to/47h8tGN
Learn more: gsk.to/47h8tGN
October 21, 2025 at 6:17 AM
#News for #Media and #Investors: Today, with Spero, we are sharing an update on the Phase III trial results of one of our investigational oral anti-infectives, presented during #IDWeek2025 in Atlanta.
Learn more: gsk.to/47h8tGN
Learn more: gsk.to/47h8tGN
“It’s hard to explain the pain of a UTI to people who’ve never had one.”
🔗 Read LeAnn’s story and why she thinks personalised care is so important: gsk.to/4hkD8aO
#IDWeek2025
🔗 Read LeAnn’s story and why she thinks personalised care is so important: gsk.to/4hkD8aO
#IDWeek2025
October 19, 2025 at 11:00 AM
“It’s hard to explain the pain of a UTI to people who’ve never had one.”
🔗 Read LeAnn’s story and why she thinks personalised care is so important: gsk.to/4hkD8aO
#IDWeek2025
🔗 Read LeAnn’s story and why she thinks personalised care is so important: gsk.to/4hkD8aO
#IDWeek2025
Modern medicine has revolutionised the way we live but the challenges to our health are evolving. Find out why preventing disease is the best investment not just for people but also for the world’s health systems, societies and economies 👇
#IDWeek2025
#IDWeek2025
'Prevention is the best medicine to stop disease before it starts' | GSK
Investing in prevention delivers better health outcomes for patients, is cost-effective, and boosts the economy
gsk.to
October 18, 2025 at 11:00 AM
Modern medicine has revolutionised the way we live but the challenges to our health are evolving. Find out why preventing disease is the best investment not just for people but also for the world’s health systems, societies and economies 👇
#IDWeek2025
#IDWeek2025
Understanding the challenges faced by those living with gynaecologic cancers is key to driving change.
Visit us at #ESMO25 to learn more about our Your Cancer Is Our Challenge survey and how we’re working to amplify patient voices and improve care.
🔗 Learn more: bit.ly/4h9h2YB
Visit us at #ESMO25 to learn more about our Your Cancer Is Our Challenge survey and how we’re working to amplify patient voices and improve care.
🔗 Learn more: bit.ly/4h9h2YB
October 18, 2025 at 8:00 AM
Understanding the challenges faced by those living with gynaecologic cancers is key to driving change.
Visit us at #ESMO25 to learn more about our Your Cancer Is Our Challenge survey and how we’re working to amplify patient voices and improve care.
🔗 Learn more: bit.ly/4h9h2YB
Visit us at #ESMO25 to learn more about our Your Cancer Is Our Challenge survey and how we’re working to amplify patient voices and improve care.
🔗 Learn more: bit.ly/4h9h2YB